HHS Drug Cost Forum: Merck, Novartis To Represent Industry View
This article was originally published in The Pink Sheet Daily
Executive Summary
The two big pharmas are the only representatives of branded drug manufacturers scheduled to participate in the meeting. GPhA’s Chip Davis is on the agenda to represent the generic drug industry's point of view.
You may also be interested in...
HHS Raises Profile In Drug Costs Discussion
On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.